The upregulated CXCL12/CXCR4 signaling pathway in GBM contributes to an immunosuppressive tumor immune microenvironment (TIME) and tumor progression, with AMD3100 as a CXCR4 inhibitor. This evidence concerns the gene CXCL12 and neoplasm.